Efficacy of Atezolizumab in Subsequent Lines of Therapy for NSCLC Patients: Insights from Real-World Data
Milica Kontić, Filip Marković, Nikola Nikolić, Natalija Samardžić, Goran Stojanović, Petar Simurdić, Svetlana Petkov, Daliborka Bursać, Bojan Zarić, Mihailo Stjepanović, Nagio Takigawa · 2024
Read Efficacy of Atezolizumab in Subsequent Lines of Therapy for NSCLC Patients: Insights from Real-World Data by Milica Kontić, Filip Marković, Nikola Nikolić, Natalija Samardžić, Goran Stojanović, Petar Simurdić, Svetlana Petkov, Daliborka Bursać, Bojan Zarić, Mihailo Stjepanović, Nagio Takigawa (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11545278.txt.
Description
Simple SummaryThis study analyzes real-world outcomes for advanced, non-oncogene addicted non-small cell lung cancer patients treated with atezolizumab monotherapy following platinum-based chemotherapy, based on data from two academic institutions in Serbia. Progression-free survival did not significantly differ between patients receiving atezolizumab as a second, third, or later line of therapy, indicating consistent efficacy across treatment lines.
Catalog record
| CREATOR | Milica Kontić, Filip Marković, Nikola Nikolić, Natalija Samardžić, Goran Stojanović, Petar Simurdić, Svetlana Petkov, Daliborka Bursać, Bojan Zarić, Mihailo Stjepanović, Nagio Takigawa |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |